A Phase 4 interventional study of Sofosbuvir/velpatasvir (Epclusa®) in Hepatitis C, Opioid-Related Disorders and Injection Drug Use, sponsored by Jennifer Havens. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Jennifer Havens · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 725 studies in Hepatitis C with a site in United States — 29 open to participants now, 37 under way, 1 of them phase 3. Hepatitis C · United States.
Among the 725 studies in Hepatitis C with a site in United States, this one is the 95th largest by enrollment of the 594 interventional ones that give a count, is one of 27 that started in 2019, is one of 85 in phase 4, and was the 644th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →29 of the 725 studies in Hepatitis C with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 16–45 · Women only
University of Washington · Sites in United States
Ages 18+
West Virginia University · Sites in United States
Ages 18+ · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18–59 · Men only · Healthy volunteers
University of Southern California · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
725 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 115 · Phase 2 186 · Phase 3 100 · Phase 4 85
First in 1981; this study’s year is marked. 27 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 380 is above the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 60 across the 594 interventional studies, 113 across the 127 observational. Of the 633 that completed or were terminated, 286 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
286 of 725 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Jennifer Havens as lead sponsor.
Jennifer Havens has 1 study filed under Hepatitis C — fewer than ten, so there is no comparison to draw.
13 of the studies in Hepatitis C with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06367465Washington University School of MedicineFeasibility and Acceptability of HCV Treatment in Pregnancy | 2026-12-28 |
| NCT06870019University of Southern CaliforniaHepatitis C Tracker Study | 2026-12-31 |
| NCT06953479LifespanImplementing Low-Barrier HCV Treatment in a Jail Setting | 2027-01 |
| NCT07631559University of California, San FranciscoPilot Study of an Adapted Partner Navigation Intervention Booster Session for Sustained Healthcare Engagement Among People Who Inject Drugs | 2027-03-01 |
| NCT06179498University of California, San FranciscoPartner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs | 2027-03-01 |
Add all 13 to your calendar (.ics) → With an account.
Among the 725 studies in Hepatitis C with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase hepatitis C virus (HCV) treatment access and delivery in a rural Appalachian community, which is in the midst of the opioid/hepatitis C (HCV) syndemic. KeY Treat is a clinical research study seeking to determine whether removing barriers (cost, insurance, specialist, abstinence) associated with accessing direct-acting antivirals (DAAs) for the treatment of HCV will impact health in Perry County, Kentucky.
The overarching goal of the Kentucky Viral Hepatitis Treatment Project (KeY Treat) is to increase access to treatment for the hepatitis C virus (HCV) in a rural Appalachian community in the midst of the opioid/HCV syndemic. This study seeks to examine whether removing barriers associated with accessing direct-acting antivirals (DAAs) for the treatment of HCV (high out-of-pocket costs, insurance restrictions requiring a specialist, abstinence, and significant liver damage) will significantly reduce the burden of HCV in Perry County, Kentucky. The proposed study is made possible by a significant drug donation from Gilead Sciences for sofosbuvir/velpatasvir, a 12-week, once per day, pan-genotypic DAA. KeY Treat proposes a multi-pronged approach to treating HCV using a mid-level provider model. In addition to DAA treatment, participants will be offered access to subsidized medication-assisted treatment, syringe services, and case management. Existing resources in the target community (public health, jail, hospital) will be leveraged, as well as ongoing projects dedicated to increasing access to HCV care in affected communities (ECHO, FOCUS) to answer whether removing the major barriers to HCV treatment affect access, and what barriers remain. All RNA-positive residents of Perry County, Kentucky will be eligible/recruited for study participation (N≈900), and the following specific aims will be addressed: 1) determination of HCV treatment uptake among rural residents with chronic HCV; 2) examination of the predictors of treatment completion among those enrolled in KeY Treat; 3) examination of the characteristics of participants achieving sustained virologic response (SVR, or cure); 4) establishment of long-term re-infection rates among those achieving SVR; 5) examination of 5-year reductions in incidence and prevalence of HCV in the intervention community compared with a control county in rural Kentucky; and 6) evaluate the impact and cost-effectiveness of KeY Treat using mathematical modeling. The proposed research has tremendous potential to impact public health in the rural United States. The majority of counties identified in CDC's recent HCV/HIV hotspot analysis were rural, and there is a real need to improve access to DAAs in order to prevent further HCV transmission, reduce the burden of advanced liver disease, and hepatocellular carcinoma in generations to come. Data from KeY Treat will inform policies around Medicaid/insurance restrictions for DAAs, and will deliver a much needed blueprint for the provision of HCV treatment in resource-deprived rural areas.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study participants will be administered a standard 12-week course of sofosbuvir/velpatasvir (Epclusa®).
Drug: Sofosbuvir/velpatasvir (Epclusa®)
After completion of the study, we will compare HCV incidence and prevalence rates in Perry County (intervention) and Pike County (control). This will be measured through data provided by the local health departments of each county. Confidential Hepatitis C screening will be conducted in some cases, and resources will be provided to those testing positive but they will not receive treatment as part of this study.
The protocol is intended to follow best practices/standard of care for the treatment of HCV, with additional allowances for the investigators to apply rigorous scientific practices for the research aspects of the study. While the treatment of HCV is fairly straightforward, less is known about treating active drug users and RNA-positive individuals in rural areas. We propose eight visits, including intake, four treatment-related visits, and three visits to determine re-infection (6- and 12-months post-SVR). Because determination of medication adherence and long-term reinfection rates are not part of standard clinical practice, the rural protocol developed at the conclusion of KeY Treat will be streamlined based on findings, consisting of five or fewer clinical contacts. The drug used for treatment is Epclusa®, a 12-week, once per day, pan-genotypic DAA with a favorable side effect profile. Vosevi® will also be available in cases where participants are non-responsive or are re-infected.
Participants Who Started HCV Treatment
Participants who received at least one dose of study medication. This is measured by number of pills left and viral load.
Time frame: Baseline through Week 12
Participants Who Completed Treatment
Treatment completion was defined as receiving all prescribed doses of medication. This is measured by pill count and viral load.
Time frame: Visit 6, 24 weeks post-baseline
Number of Participants With Sustained Virologic Response (SVR)
Defined as undetectable viral RNA at the 12-week post-completion blood draw (SVR-12).
Time frame: Visit 7, 50 weeks post-baseline
Number of Participants for Follow-Up Re-Infection Assessment
Defined as the presence of viral RNA at either the 6- or 12-month follow-up after achieving SVR.
Time frame: Visit 8, 102 weeks post-baseline
Prevalence of HCV
Prevalence of HCV in study population, measured by viral load.
Time frame: Visit 8, 102 weeks post-baseline
Incidence of HCV
State surveillance data required to calculate HCV incidence were unavailable during the study period; therefore this outcome could not be evaluated.
Time frame: Visit 8, 102 weeks post-baseline
| Milestone | HCV Positive Study Participants | Control (Pike County) |
|---|---|---|
| Started | 370 | 0 |
| Completed | 250 | 0 |
| Not completed | 120 | 0 |
| Withdrew: Lost to follow-up | 118 | 0 |
| Withdrew: Death | 2 | 0 |
| Milestone | HCV Positive Study Participants | Control (Pike County) |
|---|---|---|
| Started | 250 | 0 |
| Completed | 233 | 0 |
| Not completed | 17 | 0 |
| Withdrew: Death | 4 | 0 |
| Withdrew: Lost to follow-up | 13 | 0 |
| Milestone | HCV Positive Study Participants | Control (Pike County) |
|---|---|---|
| Started | 233 | 0 |
| Completed | 215 | 0 |
| Not completed | 18 | 0 |
| Withdrew: Death | 11 | 0 |
| Withdrew: Lost to follow-up | 7 | 0 |
Participants who received at least one dose of study medication. This is measured by number of pills left and viral load.
| Participants | HCV Positive Study Participants | Control (Pike County) |
|---|---|---|
| Participants Who Started HCV Treatment | 370 | 0 |
Treatment completion was defined as receiving all prescribed doses of medication. This is measured by pill count and viral load.
| Participants | HCV Positive Study Participants | Control (Pike County) |
|---|---|---|
| Participants Who Completed Treatment | 250 | — |
Defined as undetectable viral RNA at the 12-week post-completion blood draw (SVR-12).
| Participants | HCV Positive Study Participants | Control (Pike County) |
|---|---|---|
| Number of Participants With Sustained Virologic Response (SVR) | 233 | 0 |
Defined as the presence of viral RNA at either the 6- or 12-month follow-up after achieving SVR.
| Participants | HCV Positive Study Participants | Control (Pike County) |
|---|---|---|
| Number of Participants for Follow-Up Re-Infection Assessment | 8 | 0 |
Prevalence of HCV in study population, measured by viral load.
| Participants | HCV Positive Study Participants | Control (Pike County) |
|---|---|---|
| Prevalence of HCV | 370 | 0 |
State surveillance data required to calculate HCV incidence were unavailable during the study period; therefore this outcome could not be evaluated.
No measurements were reported for this outcome.
Collected over From initiation of study treatment through the final follow-up visit (approximately 50 weeks post-baseline). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HCV Positive Study Participants | 41/380 (10.8%) | 0/380 (0%) | 0/380 (0%) |
| Control (Pike County) | — | — | — |
Pike was unable to provide data.
| Age, Continuous(years) | HCV Positive Study Participants | Control (Pike County) | Total |
|---|---|---|---|
| Mean | 42.2 ± 0.48 | — | 42.2 ± 0.48 |
| Sex: Female, Male(Participants) | HCV Positive Study Participants | Control (Pike County) | Total |
|---|---|---|---|
| Female | 157 | — | 157 |
| Male | 223 | — | 223 |
| Ethnicity (NIH/OMB)(Participants) | HCV Positive Study Participants | Control (Pike County) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | — | 0 |
| Not Hispanic or Latino | 380 | — | 380 |
| Unknown or Not Reported | 0 | — | 0 |
| Race (NIH/OMB)(Participants) | HCV Positive Study Participants | Control (Pike County) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | — | 0 |
| Asian | 0 | — | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | — | 0 |
| Black or African American | 13 | — | 13 |
| White | 367 | — | 367 |
| More than one race | 0 | — | 0 |
| Unknown or Not Reported | 0 | — | 0 |
| Region of Enrollment(participants) | HCV Positive Study Participants | Control (Pike County) | Total |
|---|---|---|---|
| United States | 380 | — | 380 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Sep 2019 to primary completion in Jun 2025, 69 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 56 non-industry phase 4 interventional studies under Hepatitis C, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 49. This study's 69 months is above that.
Counting every sponsor, half of 58 studies reached it within 24 months; a quarter within 16 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.